Previous data from the phase II CALYPSO study has demonstrated the efficacy of durvalumab in combination with savolitinib.
nccRCC
Advertisement
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
New data shows patients with nccRCC may benefit from adjuvant therapy at a comparable rate as patients with ccRCC.
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC.
In part 2, new trials in the nccRCC treatment landscape are reviewed, and the use of IO/TKI and PD-L1 are discussed.
In the first segment of this roundtable series, the panelists discuss the management of papillary metastatic nccRCC.
Drs. Karine Tawagi and Christopher Wallis review the SUNNIFORECAST and TiNivo-2 trials at the ESMO Congress 2024.
The combination of ipilimumab/nivolumab may be a new standard in some subgroups of patients with metastatic nccRCC.
Drs. Barata and Tawagi provide updates in nccRCC, including SAMETA, PAPMET2, SUNNIFORECAST, and updated NCCN guidelines.
Conference Coverage
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease.
Dr. Antonarakis discusses the differences between PARP1 mRNA expression and other biomarkers used for risk stratification.
Advertisement
Advertisement
Latest News
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
CA9 imaging and ZIRCON data offer new insight into managing small renal masses and supporting personalized kidney cancer care
Drs. Joyce and Chang discuss diagnostic strategies and future innovations in managing small renal masses.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.